Partnership to Accelerate APAC Preclinical Drug Development

TransCure bioServices, a humanised mouse model CRO, has forged a strategic collaboration with Preclina Inc, a leading South Korean preclinical CRO specialising in autoimmune and inflammatory diseases. This partnership marks a significant milestone for TransCure as it extends its presence into the APAC region and fortifies its service portfolio, thereby enhancing the quality of its research outcomes.

By teaming up with Preclina Inc, TransCure bioServices can now offer biotechnology and pharmaceutical companies in the APAC region enhanced access to cutting-edge mouse models and a comprehensive suite of services essential for optimised preclinical development.

In the APAC region, drug developers have traditionally encountered numerous challenges during preclinical development. These challenges include restricted availability of animal model providers, inadequate breadth and capacity of service offerings, and a lack of comprehensive, all-in-one preclinical partners. Additionally, mouse model providers in the region may not always utilise standardised, widely recognised model sets commonly used in international research, resulting in difficulties when comparing research results.

The collaboration between TransCure bioServices and Preclina serves as a direct response to these challenges, presenting APAC customers with a comprehensive solution. By joining forces, they offer a complete array of cutting-edge preclinical services all in one place, along with access to the most advanced and internationally recognised mouse models and cell lines. This partnership empowers drug developers in the region to enhance and streamline their preclinical programs,

"TransCure’s one-stop-shop offering spans three platforms, more than 50 proven animal models, and a vast selection of technical services," said Kiave Ho Wang Yin, PhD, Chief Business Officer at TransCure bioServices. "By joining forces with Preclina, we further bolster those offerings with extensive autoimmune and inflammatory disease expertise, unlocking new insights for APAC-based developers, while bringing our renowned partnership-rather-than-supplier approach to the region. With this foothold, we’re uniquely positioned to grow our capacity in the region and further innovate for the benefit of our sponsors.”

Preclina is renowned for its exceptional expertise in autoimmune and inflammatory disorders, encompassing conditions like NASH, fibrosis, arthritis, and scleroderma. Leveraging its profound understanding of immunology, the company excels in utilising patient-derived cells and animal models that faithfully replicate these complex disorders. With a fully integrated drug discovery platform, Preclina has become an indispensable partner for APAC clients engaged in the development of novel drugs, diagnostic tools, and treatment technologies.

"Combining our know-how and services with TransCure’s offers a unique opportunity to better address the preclinical needs of APAC customers," said Young Mo Kang, PhD, CEO at Preclina. "We’re delighted that this partnership will further augment the high-quality, comprehensive services we’re well known for. We look forward to delivering the fruits of this collaboration to our customers, helping them carve a smoother route to better preclinical research for transformative therapeutics and diagnostics."